Hinova Pharmaceuticals Inc. reported earnings results for the nine months ended September 30, 2023. For the nine months, the company reported net loss was CNY 238.05 million compared to CNY 222.53 million a year ago. Basic loss per share from continuing operations was CNY 2.4 compared to CNY 2.48 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
30.26 CNY | +1.71% | +12.07% | -41.89% |
Apr. 26 | Hinova Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 08 | China Stocks Fall Ahead of March Economic Data Release | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.89% | 414M | |
+64.23% | 62.59B | |
-2.31% | 41.18B | |
+44.36% | 40.29B | |
-8.29% | 27.9B | |
+11.97% | 26.21B | |
-21.16% | 19.09B | |
+7.54% | 13.08B | |
+27.17% | 12.05B | |
+25.72% | 12.26B |
- Stock Market
- Equities
- 688302 Stock
- News Hinova Pharmaceuticals Inc.
- Hinova Pharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023